GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Shiller PE Ratio

SCYNEXIS (LTS:0L49) Shiller PE Ratio : (As of May. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


SCYNEXIS Shiller PE Ratio Historical Data

The historical data trend for SCYNEXIS's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Shiller PE Ratio Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SCYNEXIS's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Shiller PE Ratio falls into.



SCYNEXIS Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

SCYNEXIS's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, SCYNEXIS's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.01/131.7762*131.7762
=0.010

Current CPI (Mar. 2024) = 131.7762.

SCYNEXIS Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -9.800 100.560 -12.842
201409 -4.500 100.428 -5.905
201412 -3.613 99.070 -4.806
201503 -7.500 99.621 -9.921
201506 -7.800 100.684 -10.209
201509 -6.009 100.392 -7.888
201512 -5.900 99.792 -7.791
201603 -5.200 100.470 -6.820
201606 -5.600 101.688 -7.257
201609 -4.800 101.861 -6.210
201612 -0.500 101.863 -0.647
201703 -2.500 102.862 -3.203
201706 -1.600 103.349 -2.040
201709 -3.100 104.136 -3.923
201712 -2.700 104.011 -3.421
201803 -1.200 105.290 -1.502
201806 -2.300 106.317 -2.851
201809 0.100 106.507 0.124
201812 0.600 105.998 0.746
201903 -4.600 107.251 -5.652
201906 -1.580 108.070 -1.927
201909 -1.450 108.329 -1.764
201912 -2.140 108.420 -2.601
202003 -0.720 108.902 -0.871
202006 -0.640 108.767 -0.775
202009 -0.280 109.815 -0.336
202012 -3.920 109.897 -4.700
202103 -0.230 111.754 -0.271
202106 -0.220 114.631 -0.253
202109 -0.060 115.734 -0.068
202112 -1.110 117.630 -1.243
202203 -0.180 121.301 -0.196
202206 -0.310 125.017 -0.327
202209 -0.620 125.227 -0.652
202212 -0.290 125.222 -0.305
202303 -0.710 127.348 -0.735
202306 2.460 128.729 2.518
202309 -0.040 129.860 -0.041
202312 -0.410 129.419 -0.417
202403 0.010 131.776 0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SCYNEXIS  (LTS:0L49) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


SCYNEXIS Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines